Abstracts tagged "Therapy, complementary"

Abstract Number: 0420 • ACR Convergence 2025
Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Pernille Büyesen¹, Anna-Birgitte Aga¹, Vibke Lilleby¹, Maiju Pesonen¹, Marite Rygg², Ellen Nordal³, Bjørn Barstad⁴, Karin Tylleskär⁵, Helga Sanner¹, Siri Hetlevik¹, Nina Martine Sande¹, Inge Christoffer Olsen¹, Siri Lillegraven⁶, Espen Haavardsholm⁷, Athimalaipet Ramanan⁸, Oyvind Molberg⁹ and Berit Flatø¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ³University Hospital of North Norway, Tromsø, Nepal, ⁴Stavanger University Hospital, Stavanger, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Bristol Royal Hosp for Children, Bristol, United Kingdom, ⁹Oslo University Hospital, Oslo, Nepal
Background/Purpose: Modern therapies have improved outcomes in patients with JIA, but up to 60% of patients treated with TNF-α inhibitors (TNFi) have persisting disease activity…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Beatriz Vellón-García¹, Gema Dolores García-Delgado², Adrián Llamas Urbano³, Yas Hanaee³, Pedro Ortiz Buitrago⁴, Christian Merlo⁵, Maria del carmen abalos-aguilera⁵, julio Manuel Martinez Moreno⁶, Iván Arias de la Rosa⁷, María Dolores López-Montilla⁸, Rafaela Ortega-Castro⁹, Jerusalén Calvo¹⁰, Lourdes Ladehesa¹¹, Clementina López Medina¹², María Ángeles Puche-Larrubia¹³, Nuria Barbarroja¹⁴, Eduardo Collantes estévez¹⁵, Alejandro Escudero-contreras⁵, Chary López pedrera¹⁶, Jose manuel Villalba¹⁷ and Carlos Pérez Sánchez¹⁸, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ³Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁶Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹⁰IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹¹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ¹³Reina Sofia University Hospital, Granada, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁷Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
Abstract Number: PP07 • ACR Convergence 2025
Beyond the Medication: Creating a Toolbox of Complementary Therapies
Brittany Murray
Background/Purpose: For over 30 years, I have been living with Psoriatic Disease, diagnosed with Psoriasis at 2 years old and Psoriatic Arthritis at 14. My…
Abstract Number: 2704 • ACR Convergence 2025
Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
Hubert De Boysson¹, Anael Dumont², Thibault Orvain², Olivier Espitia³, Cloé Comarmond⁴, Samuel Deshayes⁵, Laurent Sailler⁶, Jean-François Alexandra⁷, Maxime Samson⁸ and Achille Aouba⁵, ¹Internal Medicine, CHU Caean, Caen, France, ²Caen University Hospital, Caen, Basse-Normandie, France, ³CHU de Nantes, Nantes, France, ⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ⁵Caen University Hospital, Caen, France, ⁶CHU Toulouse, Toulouse, France, ⁷Internal Medicine, Hôpital Bichat, APHP, Paris, France, ⁸CHU Dijon Bourgogne, Dijon, France
Background/Purpose: Persistent large-vessel vasculitis (LVV) on PET/CT in giant-cell arteritis (GCA) is associated with a higher risk of aortic dilation. Few data are available on…
Abstract Number: 2552 • ACR Convergence 2025
Effects of 360° Virtual Reality Embodiment Videos on Pain in Hand Osteoarthritis: A Within-Subject Pre-Post Study
David Vo¹, Robert Edwards² and Nancy Baker³, ¹Tufts University, Huntington Beach, CA, ²Brigham and Womens Hospital, Chestnut Hill, MA, ³Tufts University, Medford, MA
Background/Purpose: Osteoarthritis (OA) is associated with chronic pain in the joints, which affects many individuals’ daily function and quality of life. The sense of embodiment…
Abstract Number: 2517 • ACR Convergence 2025
Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Koushik Varma Sangaraju⁶, Veena Katikineni⁷ and Anastasia Slobodnick⁸, ¹Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, staten island, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶St. Luke's University Health Network, Bethlehem, PA, ⁷Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁸Northwell, Staten Island, NY
Background/Purpose: Plasmapheresis (PLEX) has a compelling rationale in its ability to remove pathogenic ANCAs, in the management of ANCA-associated vasculitis (AAV), particularly in patients with…
Abstract Number: 2513 • ACR Convergence 2025
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
Iñigo Rúa-Figueroa¹, Beatriz Velasco² and Maria Cid³, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²GSK, Madrid, Spain, ³Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by systemic necrotizing vasculitis affecting small and medium-sized vessels, and defined by the presence of eosinophilia, extravascular…
Abstract Number: 1600 • ACR Convergence 2025
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Fabricio Benavides Villanueva¹, Andrea Tristan-Alonso², Carlos Martinez-Rivera³, Alicia Padilla-Galo⁴, Marina Blanco-Aparicio⁵ and Ricardo Blanco⁶, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, ³Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁴Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, ⁵Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, ⁶Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1046 • ACR Convergence 2025
Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center, LLC, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: As medical cannabis becomes increasingly integrated into clinical care, healthcare providers—particularly those managing chronic rheumatologic conditions—must navigate wide-ranging levels of knowledge, attitudes, and prescribing…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: 0896 • ACR Convergence 2025
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
marc Corbera-bellalta¹, Nuria Farran-Centelles², Nina Visocnik¹, Sergio Prieto-Gonzalez³, Jose hernandez-rodriguez⁴, javier Marco-hernandez⁵, Georgina Espigol-Frigolé¹ and Maria Cid⁶, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Autoimmune diseases, Barcelona, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic. University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁵Hospital Clinic.University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁶Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Patients with giant-cell arteritis (GCA) are in an unmet need for reduction of GC exposure because of the high incidence of GC-related side effects…
Abstract Number: 0732 • ACR Convergence 2025
Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
marc Corbera-bellalta¹, Roser Alba-Rovira¹, Nina Visocnik¹, Farah Kamberovic¹, Ferran Araujo-Ayala¹, Georgina Espigol-Frigolé¹, Patricia Perez-Galán¹, Ken Bondensgaard², John Paolini³ and Maria Cid⁴, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Kiniksa Pharmaceuticals, Lexington, ³Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁴Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Background: Giant-cell arteritis(GCA) is a chronic inflammatory disease targeting large and medium-sized arteries. Inflammation-induced vascular remodeling leads to vascular occlusion, with ischemic complications. Myofibroblasts…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].